The number of patients with Crohn’s disease who receive biologic therapy is strongly correlated with the gross domestic product in 10 European countries, according to a recent analysis.
The number of patients with Crohn’s disease (CD) who receive biologic therapy is strongly correlated with the gross domestic product (GDP) in 10 European countries, according to a recent analysis published in the September 2017 issue of the World Journal of Gastroenterology. Authors Martá Péntek, MD, PhD, and colleagues with the Crohn’s Disease Research Group in Hungary note that the high price and budget impact of biologics has led most countries to regulate reimbursed treatment, and differences in regulations have caused disparities in access to these drugs, even among European countries with similar economic situations.
The study was based on a questionnaire survey of gastroenterologists, combined with a literature-based research conducted in May 2016. Both data sources provided information on the availability of originator biologics and biosimilars, reimbursement criteria, clinical practices, prices, and use of originator biologics and biosimilars in the Czech Republic, France, Germany, Hungary, Latvia, Poland, Romania, Slovakia, Spain, and Sweden (all nations with socialized or partially socialized health systems). At the time of the survey, infliximab and adalimumab were reimbursed in all 10 countries, and vedolizumab was reimbursed in 5. Biosimilar infliximab products were available in some countries, but regulations and restrictions guiding their use varied.
Péntek and colleagues studied the influence of the following factors on access to CD treatment with biologics—originators and biosimilars:
The study found differences in how the 10 countries addressed reimbursement criteria and costs. For example:
The study authors note that the 10 countries differ not only with respect to their economic development but also the ways in which they organize and finance their healthcare system, which can influence access to biological treatments. Although access to originator biologics and biosimilars was strongly determined by the economic development of the country, the differences found cannot be entirely explained by the availability or affordability. Therefore, the authors recommend further exploration of the issues the guiding acceptance of and attitudes toward biologicals.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Meta-Analysis Confirms Similar Safety, Efficacy Between Adalimumab Biosimilars, Humira
April 6th 2024A systematic review and meta-analysis of 7 randomized controlled trials found no significant differences in efficacy and safety indicators between adalimumab biosimilars and the reference product (Humira) for treatment of moderate to severe psoriasis.